Elevai Labs, Inc. (Ticker: ELAB) is an innovative technology firm at the forefront of artificial intelligence and machine learning, primarily catering to the healthcare and finance sectors. By leveraging sophisticated data analytics, the company empowers organizations to extract actionable insights from intricate datasets, thus enhancing operational efficiencies and supporting strategic decision-making. Positioned strategically within a dynamic technology landscape, Elevai Labs is well-prepared to harness emerging market trends for growth, underscoring its commitment to advancing AI technologies and solidifying its role as a significant player with strong potential for sustainable development and competitive advantage.
| Revenue (TTM) | $2.58M |
| Gross Profit (TTM) | -528,822 |
| EBITDA | $-11.54M |
| Operating Margin | -290.00% |
| Return on Equity | -105.20% |
| Return on Assets | -33.00% |
| Revenue/Share (TTM) | $1.91 |
| Book Value | $2.72 |
| Price-to-Book | 0.33 |
| Price-to-Sales (TTM) | 1.54 |
| EV/Revenue | 0.0386 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -45.80% |
| Shares Outstanding | $4.54M |
| Float | $7.29M |
| % Insiders | 9.99% |
| % Institutions | 5.87% |
Volatility is currently contracting
PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-o
Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization Company Reports 8,095,835 Shares of Common Stock Issued and Outstanding as of July 29, 2026, and Moves to Correct Third-Party Market Data That Understates Its Current Share Count and Market Capitalization
PMGC Holdings Inc.
NorthStrive Defense Tech Engages Defense Software and Security Firm Deploy360 to Validate Patented GPS-Denied Drone Navigation Technology Under Option to L
NorthStrive Defense Tech Executes Definitive Exclusive License Agreement with Florida State University Research Foundation for Multi-Domain Drone Payload T
Independent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd. Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists NEWPORT BEACH, Calif.
Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies' aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that it has merged AGA Precision Systems LLC (“AGA”) into A&B Aerospace, Inc. (“A&B Aerospace”), with A&B Aerospace expected to be the surviving operating entity.
Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy
Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development.
Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss Filed applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications for the preservation of lean muscle mass during GLP-1 and obesity-related weight loss.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ELAB and any ticker you trade — then tracks every position and per-strategy win rate.
